HIF1-α appears to modulate human leukocyte antigen-G (HLA-G) expression, a tolerogenic molecule proposed as an immune checkpoint [136,137], and the HIF1A-rs2244608 polymorphism has been associated with the efficacy of irinotecan-based CRC therapy. This evidence concerns the gene HLA-G and colorectal carcinoma.